Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)

Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)

Abstract Background The survival rate for patients with relapsed and refractory acute myeloid leukaemia (R/R-AML) remains poor, and treatment is challenging. Chimeric antigen receptor T cells (CAR-T cells) have been widely used for haematologic malignancies. Current CAR-T therapies for acute myeloid...

Full description

Bibliographic Details
Main Authors: Yu Lu, Ying Liu, Shupeng Wen, Na Kuang, Xuejun Zhang, Jianqiang Li, Fuxu Wang
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Journal of Translational Medicine
Subjects:
Acute myeloid leukemia1
CD72
CAR-T cells3
Immunotherapy4
Minimal Residual disease (MRD)5
Online Access:https://doi.org/10.1186/s12967-022-03797-7

Internet

https://doi.org/10.1186/s12967-022-03797-7

Similar Items